Need More Justification: CDSCO Panel rejects J&J protocol amendment proposal for Teclistamab study

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-17 12:15 GMT   |   Update On 2024-03-21 15:28 GMT
Advertisement

New Delhi: Citing that more justification is required, the Subject Expert Committee SEC functional under the Central Drug Standard Control Organisation (CDSCO) has rejected Johnson & Johnson's protocol amendment proposal for the anti-cancer drug Teclistamab study.

This came after the firm presented protocol amendment 3.0 dated 14 June 2023 protocol No. 64007957MMY3005.

This is a study of Teclistamab in combination with Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in combination with Daratumumab and Lenalidomide (Tal-DR) in participants with newly diagnosed multiple myeloma (MajesTEC-7).

Advertisement

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Teclistamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager used to treat relapsed and refractory multiple myeloma in adults as monotherapy.

Teclistamab binds to a protein called CD3, which is found in T cells (a type of white blood cell). It also binds to a protein called BCMA, which is found on myeloma cells and some B cells (another type of white blood cell). This may help the immune system kill cancer cells.

At the recent SEC meeting for Oncology held on 21st February 2023, the expert panel reviewed the presented protocol amendment 3.0 dated 14 June 2023 protocol No. 64007957MMY3005.

After detailed deliberation, the committee opined that due to significant drug-related toxicity, the protocol amendment may not be considered at this stage and more justification is required to be submitted for further review by the committee.

Also Read: CDSCO panel Rejects Akum Pharma's FDC Bempedoic acid plus Atorvastatin Calcium plus Ezetimibe

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News